Barclays Issues Pessimistic Forecast for Owens & Minor (NYSE:OMI) Stock Price

Owens & Minor (NYSE:OMI) had its price objective dropped by stock analysts at Barclays from $18.00 to $14.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s price target would indicate a potential upside of 2.87% from the company’s previous close.

OMI has been the topic of several other reports. Robert W. Baird lowered their price objective on Owens & Minor from $19.00 to $14.00 and set a “neutral” rating on the stock in a research report on Tuesday. StockNews.com downgraded Owens & Minor from a “buy” rating to a “hold” rating in a research note on Monday, August 26th. JPMorgan Chase & Co. cut their price objective on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a report on Wednesday, August 21st. Finally, Citigroup raised shares of Owens & Minor from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $24.00 to $19.00 in a report on Friday, July 19th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.50.

Owens & Minor Trading Up 15.3 %

Shares of NYSE:OMI opened at $13.61 on Tuesday. Owens & Minor has a 12-month low of $11.42 and a 12-month high of $28.35. The company has a market cap of $1.05 billion, a PE ratio of -20.94, a price-to-earnings-growth ratio of 0.39 and a beta of 0.41. The stock has a 50 day moving average of $14.46 and a 200 day moving average of $16.10. The company has a current ratio of 1.09, a quick ratio of 0.51 and a debt-to-equity ratio of 2.11.

Owens & Minor (NYSE:OMI) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.68 billion. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The company’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 earnings per share. As a group, equities research analysts expect that Owens & Minor will post 1.55 EPS for the current year.

Hedge Funds Weigh In On Owens & Minor

Several institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Owens & Minor by 43,142.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,027 shares of the company’s stock worth $84,000 after buying an additional 3,020 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Owens & Minor by 118.2% during the first quarter. BNP Paribas Financial Markets now owns 47,587 shares of the company’s stock worth $1,319,000 after acquiring an additional 25,779 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Owens & Minor during the first quarter valued at approximately $358,000. Texas Permanent School Fund Corp lifted its stake in shares of Owens & Minor by 1.8% in the 1st quarter. Texas Permanent School Fund Corp now owns 66,953 shares of the company’s stock valued at $1,855,000 after purchasing an additional 1,156 shares during the last quarter. Finally, Empowered Funds LLC lifted its stake in shares of Owens & Minor by 8.2% in the 1st quarter. Empowered Funds LLC now owns 297,574 shares of the company’s stock valued at $8,246,000 after purchasing an additional 22,509 shares during the last quarter. Institutional investors own 98.04% of the company’s stock.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.